Clinical Trial: An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07669610) titled 'An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC' on June 20.

Brief Summary: This study is a prospective, open-label, phase III, randomized controlled clinical trial. It is planned to screen patients with inoperable locally advanced or metastatic triple-negative breast cancer of the BLIS subtype. A total of 140 patients are planned to be enrolled.

Study Start Date: Oct. 01, 2026

Study Type: INTERVENTIONAL

Condition: Breast Cancer Triple Negative Breast Cancer (TNBC)

Intervention: DRUG: SHR- A1811

SHRA1811(HER-targeted ADC) 4.8 mg/kg, admini...